Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors

Inclusion Criteria:

* Subjects with histologically or cytologically confirmed solid tumors who have failed or are not candidates for standard therapies or for whom no approved therapy is available.
* Eastern Cooperative Oncology Group (ECOG) performance status of greater or equal to 2.
* Medically able to tolerate a high fat meal and to fast as per protocol.
* Expected survival time of at least 3 months in the opinion of the Investigator.
* Ability to take ranitidine as per protocol.
* Must be able to swallow and retain oral medication.
* Lab values consistent with adequate renal, hepatic, and bone marrow functions.
* Electrocardiogram (ECG) with QTc of ≤450 msec for men or ≤470 msec for women and no clinically significant findings.

Exclusion Criteria:

* Pregnant (positive pregnancy test) or nursing women.
* Previous treatment with an Hsp90 inhibitor.
* Use of antacids within 7 days of Study Day 1.
* Prior antitumor therapies, including prior experimental agents or approved antitumor therapies within 28 days of the first dose of BIIB021.
* Major surgery or radiation within 28 days of the first dose of BIIB021.
* Uncontrolled, severe medical illness, which in the opinion of the Investigator and/or Sponsor could compromise protocol objectives.
* History of gastrectomy or major surgery to small intestine.
* History of exocrine pancreatic insufficiency.
* Chronic diarrhea (excess of 2 to 3 stools/day above normal frequency).
* Active bacterial or viral infection requiring concurrent treatment.
* History of hepatitis B or C or human immunodeficiency virus.
* History of central nervous system metastasis.
* Any thrombotic event occurred \<3 months prior to Day 1.
* Conditions that may predispose subjects to seizures: History of seizure, previous significant head trauma
* Drug or alcohol abuse.